𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Parathyroid hormone–related peptide as a cause of hypercalcemia in squamous cell carcinoma of the head and neck: A case presentation and subject review

✍ Scribed by J. Travis Brawner; Robert P. Zitsch

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
72 KB
Volume
26
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background.

Serum levels of parathyroid hormone–related peptide (PTHrP) can be elevated with malignancy and cause hypercalcemia, which has been associated with a poor prognosis.

Methods.

We present a case of supraglottic squamous cell carcinoma with elevated serum PTHrP and hypercalcemia. The patient was acutely managed with intravenous fluids, furosemide, and zoledronic acid and then underwent a total laryngectomy and modified radical neck dissection.

Results.

The patient remains disease free and normocalcemic.

Conclusion.

Curative treatment for patients with head and neck cancer should not be withheld solely on the basis of humoral hypecalcemia of malignancy. © 2004 Wiley Periodicals, Inc. Head Neck 26: 382–384, 2004

📜 SIMILAR VOLUMES

DNA copy number variation and loss of he
DNA copy number variation and loss of heterozygosity in relation to recurrence of and survival from head and neck squamous cell carcinoma: A review
✍ Yu Chen; Chu Chen 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 2 views

## Abstract Genetic aberrations, such as DNA copy number variation (CNV) and loss of heterozygosity (LOH), have been implicated in head and neck squamous cell carcinoma (HNSCC) initiation and progression. This review examines CNV and LOH as predictors of HNSCC recurrence and mortality. We searched

Examining expression of folate receptor
Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug
✍ Nabil F. Saba; Xu Wang; Susan Müller; Mourad Tighiouart; Kwangjae Cho; Shuming N 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 359 KB 👁 1 views

## Abstract ## Background Nanotechnology‐based drug delivery approaches may help increase therapeutic efficacy and decrease side effects of chemotherapeutics. We investigated expression levels of folate receptor in squamous cell carcinoma of the head and neck (SCCHN) to evaluate folate receptor as

Smoking tobacco, oral snuff, and alcohol
Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck : A population-based case-referent study in Sweden
✍ Freddi Lewin; Staffan E. Norell; Hemming Johansson; Per Gustavsson; Johan Wenner 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 3 views

the years 1988-1990. A total of 605 cases were identified in the base, and 756 holm, Sweden. controls were selected by stratified random sampling from population registries covering the base.

In vitro BPDE-induced DNA adducts in per
In vitro BPDE-induced DNA adducts in peripheral lymphocytes as a risk factor for squamous cell carcinoma of the head and neck
✍ Donghui Li; Pervez F. Firozi; Ping Chang; Li-E Wang; Ping Xiong; Erich M. Sturgi 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 76 KB 👁 1 views

The level of DNA adducts under the same conditions of carcinogen exposure and cell proliferation reflects an integrated measure of carcinogen metabolism and DNA repair. Therefore, such DNA adduct levels have the potential to be a biomarker for susceptibility to chemical carcinogenesis. In a pilot st

A Phase I/II trial of concurrent docetax
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck
✍ Roy B. Tishler; Charles M. Norris Jr.; A. Dimitrios Colevas; Carolyn C. Lamb; Da 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

## Abstract ## BACKGROUND The authors conducted a Phase I/II study in patients with a poor prognosis who had locally advanced squamous cell carcinoma of the head and neck (SCCHN) and who were treated initially with induction chemotherapy. Patients were treated with weekly docetaxel and concurrent